Direct Costs Associated with Multiple Myeloma Model Patient in 2017 From Single EU Jurisdiction

Economic aspects of multiple myeloma: real costs associated with disease in the Slovak Republic

“…Costs associated with family taking care of the patient with cancer were 23.2 billion[43]. Study also showed that similarly to our analysis where we took into the consideration first 12 treatment from the diagnosis, the indirect costs associated with cancer were the biggest part of total costs (66%; 133,534.60 for MM in Slovakia), but taken into the consideration the whole treatment phases from diagnosis till death, the indirect costs were 36% (147,596 ) from total costs[24]. The reason for this were prolonged treatment period with expensive technology, more hospitalizations and hundreds of laboratory tests done during the treatment period.…”

“…The imputed value of foreg or services become inefficient or are withdrawn from production on account of morbidity or premature mortality is widely regarded as an indirect cost [21]. Usually, the key stakeholders consider the direct medical costs only [22][23][24], but for full picture we also need to consider the indirect costs [25,26] paid by payers that create inevitable part of total costs evaluation.…”